However, a group of BCAR4-positive/ERBB2-low-expressing BC patients eligible for tamoxifen and lapatinib regimens has been shown not to benefit entirely from this therapy, suggesting that BCAR4 silencing may be a useful therapeutic approach just in certain subgroups of resistant BC [208]. This evidence concerns the gene ERBB2 and breast cancer.